-
Product Insights
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trial Report Overview A total of 122 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trials were conducted as of May 2024. The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial report provides a comprehensive understanding of the Chronic Inflammatory Demyelinating Polyneuropathy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent...
-
Sector Analysis
Amyotrophic Lateral Sclerosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2029
Amyotrophic Lateral Sclerosis Market Overview Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a severely debilitating, rare, and ultimately fatal neurodegenerative condition caused by a combination of genetic and environmental factors. However, the causative pathogenic mechanisms in ALS remain unclear. The condition is characterized by progressive degeneration of both upper (UMNs) and lower motor (LMNs) neurons that leads to death, frequently from respiratory failure, within a few years. The 8MM includes the US, France, Germany, Italy,...
-
Sector Analysis
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Report Overview Friedreich's Ataxia (FRDA) is a rare, genetic disorder. It is progressive and typically manifests between the ages of 10 and 15. The disorder is characterized by a gradual decline in coordination, muscle strength, and endurance. Individuals with FRDA often become reliant on wheelchairs as the condition advances. The Friedreich Ataxia (FRDA) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast,...
-
Sector Analysis
Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Report Overview Lennox-Gastaut Syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Affected children experience several different types of seizures, such as atonic, tonic, and atypical absence seizures. Children with LGS may also develop cognitive dysfunction, delays in reaching developmental milestones, and behavioral problems. Key Mechanism of Action (Marketed) ·       Receptor Agonists ·       Ion Channel Blockers ·       Enzyme Inhibitors ·       Receptor Antagonists ·       Transporter Inhibitors...
-
Sector Analysis
Metachromatic Leukodystrophy (MLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Metachromatic Leukodystrophy (MLD) Marketed and Pipeline Drugs Report Overview Metachromatic leukodystrophy (MLD), also known as globoid cell leukodystrophy (GCL), is a rare hereditary disease or lysosomal storage disease characterized by the accumulation of fats called sulfatides. This causes the destruction of the protective fatty layer surrounding the nerves in both the central nervous system (CNS) and the peripheral nervous system (PNS). Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make...
-
Sector Analysis
Dravet Syndrome (DS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Dravet Syndrome (DS) Marketed and Pipeline Drugs Report Overview Dravet syndrome is also known as severe myoclonic epilepsy of infancy (SMEI). It is a rare and severe form of epilepsy that typically begins in the first year of life. The exact cause of Dravet syndrome is usually genetic. However, seizures in affected individuals can be triggered by various factors including fever, infections, and sometimes vaccinations. These triggers can lead to prolonged and potentially life-threatening seizures known as status epilepticus. Genetic...
-
Sector Analysis
Batten Disease (BD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Batten Disease (BD) Marketed and Pipeline Drugs Report Overview Batten disease is also known as neuronal ceroid lipofuscinosis (NCL) and refers to a cluster of hereditary nervous system disorders that typically manifest in childhood. The diverse forms of the disease are categorized based on the gene responsible for the disorder. Due to the varying gene mutations that can cause the disease, the severity of symptoms and their progression rates differ. Symptoms typically include progressive vision loss leading to blindness, seizures,...
-
Sector Analysis
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Report Overview Spinal muscular atrophy (SMA) is a group of inherited neuromuscular disorders. These disorders are clinically and genetically heterogeneous. The primary feature is the loss of lower motor neurons in the spinal cord. This results in progressive muscle weakness, muscle wasting, and low muscle tone. However, neurons controlling most voluntary muscles like those involved in feeding, swallowing, and breathing can also be affected. Key Mechanism of Action (Marketed) ·      Protein or...
-
Sector Analysis
Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Report Overview Lewy body dementia (LBD) is a common type of dementia that happens when clumps of proteins called Lewy bodies build up in the brain. They damage parts of the brain that affect cognition, behavior, movement, and sleep. Lewy body intracellular inclusions result from the aggregation of misfolded α-synuclein. There will be more than 1.1 million diagnosed prevalent cases of LBD in 2023 in the 16 countries covered in GlobalData’s epidemiology...
-
Sector Analysis
Essential Tremor (ET) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
ET Marketed and Pipeline Drugs Report Overview Essential tremor (ET) is a neurological disorder that causes involuntary and rhythmic shaking in the hands, head, trunk, voice, or legs. It is one of the most common trembling disorders and is frequently confused with Parkinson's disease (PD). ET is common among people older than 40, but it can affect people at any age. The ET marketed and pipeline drugs market research report includes an assessment of the disease, leading marketed products with...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.